See more : Securitas AB (publ) (SCTBF) Income Statement Analysis – Financial Results
Complete financial analysis of NanoString Technologies, Inc. (NSTG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoString Technologies, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Gencor Industries, Inc. (GENC) Income Statement Analysis – Financial Results
- NGL Fine-Chem Limited (NGLFINE.NS) Income Statement Analysis – Financial Results
- Gyldendal A/S (GYLD-A.CO) Income Statement Analysis – Financial Results
- The Furukawa Battery Co., Ltd. (6937.T) Income Statement Analysis – Financial Results
- KG Intelligence CO., LTD. (2408.T) Income Statement Analysis – Financial Results
NanoString Technologies, Inc. (NSTG)
About NanoString Technologies, Inc.
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.26M | 145.09M | 117.32M | 125.57M | 106.73M | 114.91M | 86.49M | 62.67M | 47.59M | 31.40M | 22.97M | 17.80M | 11.73M | 34.42M |
| Cost of Revenue | 65.48M | 68.30M | 52.41M | 44.04M | 36.33M | 31.88M | 30.25M | 26.13M | 21.15M | 15.01M | 12.36M | 9.78M | 9.13M | 21.12M |
| Gross Profit | 61.79M | 76.78M | 64.91M | 81.53M | 70.40M | 83.03M | 56.24M | 36.54M | 26.44M | 16.39M | 10.61M | 8.02M | 2.60M | 13.30M |
| Gross Profit Ratio | 48.55% | 52.92% | 55.33% | 64.93% | 65.96% | 72.26% | 65.03% | 58.31% | 55.56% | 52.21% | 46.19% | 45.07% | 22.18% | 38.64% |
| Research & Development | 70.84M | 69.50M | 62.86M | 68.04M | 61.60M | 46.89M | 34.72M | 24.60M | 21.40M | 14.98M | 11.64M | 8.99M | 7.55M | 19.09M |
| General & Administrative | 133.83M | 110.70M | 86.70M | 90.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.30M | 4.80M | 3.40M | 5.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 143.13M | 115.50M | 90.10M | 96.20M | 78.20M | 74.33M | 62.70M | 53.19M | 51.06M | 29.91M | 15.49M | 9.53M | 8.03M | 36.90M |
| Other Expenses | -1.92M | -20.00K | -971.00K | -929.00K | -1.66M | 183.00K | -515.00K | -389.00K | -147.00K | -66.00K | -29.00K | 80.00K | 254.00K | 0.00 |
| Operating Expenses | 213.97M | 185.01M | 152.95M | 164.23M | 139.79M | 121.22M | 97.42M | 77.78M | 72.47M | 44.89M | 27.12M | 18.52M | 15.57M | 55.98M |
| Cost & Expenses | 279.45M | 253.31M | 205.36M | 208.27M | 176.13M | 153.10M | 127.67M | 103.91M | 93.62M | 59.90M | 39.48M | 28.30M | 24.70M | 77.10M |
| Interest Income | 2.41M | 649.00K | 1.74M | 2.82M | 1.33M | 809.00K | 390.00K | 233.00K | 272.00K | 68.00K | 21.00K | 10.00K | 29.00K | 0.00 |
| Interest Expense | 7.54M | 7.49M | 15.41M | 8.49M | 7.43M | 6.15M | 5.67M | 4.02M | 4.14M | 1.94M | 804.00K | 599.00K | 94.00K | -1.89M |
| Depreciation & Amortization | 492.00K | 629.00K | 773.00K | 1.89M | 4.07M | 3.35M | 2.98M | 2.38M | 1.54M | 1.78M | 1.95M | 1.45M | 972.00K | 0.00 |
| EBITDA | -143.58M | -101.73M | -88.05M | -82.70M | -65.65M | -34.84M | -38.32M | -39.02M | -44.31M | -26.51M | -14.96M | -8.88M | -11.70M | -42.68M |
| EBITDA Ratio | -119.20% | -74.16% | -74.39% | -64.36% | -65.32% | -32.38% | -47.75% | -66.06% | -96.44% | -90.74% | -63.42% | -50.29% | -99.89% | -123.99% |
| Operating Income | -152.18M | -108.23M | -88.05M | -82.70M | -69.39M | -38.20M | -41.18M | -41.24M | -46.02M | -28.50M | -16.51M | -10.50M | -12.97M | -42.68M |
| Operating Income Ratio | -119.58% | -74.59% | -75.05% | -65.86% | -65.02% | -33.24% | -47.61% | -65.81% | -96.70% | -90.75% | -71.86% | -58.97% | -110.59% | -123.99% |
| Total Other Income/Expenses | -7.04M | -6.86M | -21.78M | 42.27M | -7.76M | -5.16M | -5.80M | -4.17M | -4.02M | -784.00K | -1.20M | -436.00K | 204.00K | -1.44M |
| Income Before Tax | -159.23M | -115.09M | -109.83M | -40.43M | -77.15M | -43.36M | -46.97M | -45.42M | -50.04M | -29.28M | -17.71M | -10.93M | -12.77M | -44.12M |
| Income Before Tax Ratio | -125.12% | -79.32% | -93.61% | -32.20% | -72.28% | -37.73% | -54.31% | -72.47% | -105.14% | -93.24% | -77.08% | -61.42% | -108.85% | -128.17% |
| Income Tax Expense | 317.00K | 167.00K | 253.00K | 269.00K | 249.00K | 204.00K | 116.00K | 166.00K | 2.45M | 99.00K | 775.00K | 679.00K | 348.00K | 5.00K |
| Net Income | -159.54M | -115.25M | -110.08M | -40.70M | -77.40M | -43.56M | -47.09M | -45.58M | -50.04M | -29.28M | -17.71M | -10.93M | -12.77M | -44.11M |
| Net Income Ratio | -125.37% | -79.44% | -93.83% | -32.41% | -72.52% | -37.91% | -54.45% | -72.74% | -105.14% | -93.24% | -77.08% | -61.42% | -108.85% | -128.16% |
| EPS | -3.44 | -2.54 | -2.82 | -1.18 | -2.78 | -1.84 | -2.34 | -2.40 | -2.80 | -3.83 | -1.93 | -1.19 | -1.59 | -0.95 |
| EPS Diluted | -3.44 | -2.54 | -2.82 | -1.18 | -2.78 | -1.84 | -2.34 | -2.40 | -2.80 | -3.83 | -1.93 | -1.19 | -1.59 | -0.95 |
| Weighted Avg Shares Out | 46.41M | 45.30M | 39.08M | 34.59M | 27.88M | 23.73M | 20.12M | 19.03M | 17.84M | 7.64M | 9.17M | 9.17M | 8.02M | 46.66M |
| Weighted Avg Shares Out (Dil) | 46.41M | 45.30M | 39.08M | 34.59M | 27.88M | 23.73M | 20.12M | 19.03M | 17.84M | 7.64M | 9.17M | 9.17M | 8.02M | 46.66M |
NanoString to Release Fourth Quarter and Fiscal Year 2022 Operating Results and Host Conference Call on Tuesday, February 28, 2023
NanoString Showcases Ultra High-Plex 6K RNA Single Cell Imaging at the 2023 Advances in Genome Biology and Technology (AGBT)
Weill Cornell Medicine and NanoString Collaborate to Create Comprehensive Spatial Atlas of Human Anatomy
NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager
NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2022
NanoString to Present at the 41st Annual J.P. Morgan Healthcare Conference
NanoString's CosMx Spatial Molecular Imager Recognized by The Scientist Magazine as a Top 10 Innovation of 2022
NanoString Begins Commercial Shipments of CosMx Spatial Molecular Imager and AtoMx Spatial Informatics Platform
NanoString to Webcast Presentations from Two Upcoming Healthcare Conferences
NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research
Source: https://incomestatements.info
Category: Stock Reports